The global autoinjectors market is projected to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%. Technology advancements in autoinjector devices, such as improved design, the addition of connectivity features for data tracking, Bluetooth connectivity, and dosage reminders, are some of the factors that increase the adoption of autoinjectors and drive market growth. The prevalence of severe allergies also leads to a significant demand for products such as EpiPen (epinephrine autoinjectors), which are essential for emergency treatment in developed and emerging economies.
Download an Illustrative overview:
Global Autoinjectors Market Dynamics
Driver: Increasing regulatory approvals for autoinjectors
Favorable regulatory scenarios and frequent authorizations for novel autoinjector devices are significant factors that uplift market growth. The US FDA has approved biologics such as Humira (adalimumab) to treat rheumatoid arthritis, which, in turn, further drives the global demand for autoinjectors. Introducing new categories, such as GLP-1, has also resulted in fewer injections and more compliance with treatment programs. Furthermore, using technologically advanced autoinjectors has improved disease management by allowing dosage tracking and data exchange. For example, in 2024, LEO Pharma got US FDA clearance for Adbry (tralokinumab-ldrm), which is licensed for atopic dermatitis in adults and children (12 years and older).
Restraint: Focus on needle-free drug delivery systems and prevalence of needle phobia
Traditional injectables with vials and syringes are invasive and painful modes of drug delivery, owing to which patients and care providers have focused on alternative routes such as oral, topical, and nasal routes. The oral route is preferred because it is convenient, cost-effective, safe, and acceptable. The market is likely to experience a negative impact on future growth due to the introduction of needle-free drug delivery devices, such as jet injectors. For example, Crossject offers ZENEO, a needle-free autoinjector, and PharmaJet provides the Stratis Needle-free Injection System.
Opportunity: Launch of technologically advanced autoinjectors
Investment in the launch of technologically advanced autoinjectors with smart connectivity has propelled the market growth. The launch of advanced autoinjectors with integration of Bluetooth data connectivity with smartphones further creates lucrative growth opportunities in the coming years. For instance, the currently available RebiSmart autoinjector used for multiple sclerosis is designed with built-in Bluetooth connectivity, which allows patients to track their injection history using a smartphone app.
The adoption of advanced polymers and other materials in autoinjectors has also increased the tenure and performance of these devices, allowing for constant operation in various conditions. Technological improvements have altered the autoinjector market by improving the devices' intelligence, comfort, and use. These advancements help patients comply with therapy, reduce mistake risks, and ultimately improve health outcomes. All the variables listed above are projected to promote market expansion in the future.
Challenge: Development of autoinjectors for multiple drug viscosities
Autoinjectors help deliver an accurate volume of drugs/medications at a precise injection speed, and these parameters can be hampered by the viscosity of the drug to be given in the form of an autoinjector. Viscosity refers to the resistance or thickness of a liquid flow, which can be affected by factors such as biologics, chemical properties, and the strength of the active ingredient.
North America was the largest regional market for the Autoinjectors market
North America dominated the global autoinjector devices and finished formulations market in 2023 and will likely dominate throughout the forecast period. The rising adoption of self-administration among patient populations and cost-effectiveness boost the market growth. Also, the high prevalence of chronic diseases, favorable regulatory environment, and adequate reimbursement policies spur market growth.
This report categorizes the autoinjectors market into the following segments:
Autoinjectors Market, by Usage
· Disposable Autoinjectors
· Reusable Autoinjectors
Autoinjectors Market, by Technology
· Manual Autoinjectors
· Automatic Autoinjectors
Autoinjectors Market, by Route of administration
· Subcutaneous
· Intramuscular
Autoinjectors Market, by Volume
· Upto 3ml
· Above 3ml
Autoinjectors Market, by Therapy Area
· Rheumatoid Arthritis
· Diabetes
· Multiple Sclerosis
· Anaphylaxis
· Obesity
· Other therapy areas
Autoinjectors Market, by End User
· Home Care Settings
· Hospitals & Clinical Settings
· Ambulatory Care Settings
Autoinjectors Market, by Region
· North America
· Europe
· Asia Pacific (APAC)
· Latin America
· Middle East & Africa
Content Source:
https://www.marketsandmarkets.com/PressReleases/autoinjector.asp
https://www.marketsandmarkets.com/ResearchInsight/autoinjector-market.asp
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
